Antiobesity pharmacotherapy in the management of type 2 diabetes.
Obesity is a well-known risk factor for the development of Type 2 diabetes mellitus. The management of the obese diabetic patient remains a challenge for the clinician but, in any case, weight reduction should be considered as a key objective. In this respect, several antiobesity drugs have demonstrated potential. However, while fenfluramine and dexfenfluramine have been shown to promote weight loss and to directly improve insulin sensitivity, being two mechanisms contributing to better blood glucose control in obese Type 2 diabetic patients, they were recently withdrawn due to safety problems. Sibutramine, a new selective norepinephrine and serotonin reuptake inhibitor, promotes weight loss by decreasing food intake, an effect which leads to a mild improvement (significant in patients losing > or =5% of initial body weight) of blood glucose control in obese diabetic patients. Similarly, orlistat, a selective gastrointestinal lipase inhibitor which increases faecal fat losses, enhances diet-induced weight reduction and improves both blood glucose control and vascular risk profile, especially dyslipidaemia, in obese Type 2 diabetic patients. Further studies are required to better identify good responders to pharmacotherapy and specify the role of antiobesity agents in the overall long-term management of obese subjects with Type 2 diabetes. Other novel pharmacological approaches deserve further consideration, for instance beta-3 agonists aiming to increase energy expenditure, drugs interfering with tumor necrosis factor-alpha (TNF-alpha) or free fatty acid release by the adipose tissue or agents that slow gastric emptying. However, until now, results regarding efficacy and/or safety have been disappointing or preliminary in humans.
Scheen
A J
AJ
Division of Diabetes, Nutrition and Metabolic Diseases, Department of Medicine, University of Liège, CHU Sart Tilman, B-4000 Liège 1, Belgium. Andre.Scheen@chu.ulg.ac.be
Lefèbvre
P J
PJ
D001067:Appetite Depressants / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D020372:Dexfenfluramine / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D002149:Energy Intake; D005277:Fenfluramine / Q000627:therapeutic use; D006801:Humans; D009765:Obesity; D018490:Serotonin Agents / Q000627:therapeutic use
D001067:Appetite Depressants; D001786:Blood Glucose; D018490:Serotonin Agents; D005277:Fenfluramine; D020372:Dexfenfluramine